针对空间信息网络(Space Information Network,SIN)节点存储资源严重受限及存储可靠性问题,该文提出一种基于LT(Luby Transform)码的分布式存储策略(Distributed Storage Strategy based on LT codes,DSSLT)。采用定向随机漫步机制,使...针对空间信息网络(Space Information Network,SIN)节点存储资源严重受限及存储可靠性问题,该文提出一种基于LT(Luby Transform)码的分布式存储策略(Distributed Storage Strategy based on LT codes,DSSLT)。采用定向随机漫步机制,使得源数据包能够更快地遍历整个网络。在信息估计阶段利用基于ID的估计方法进行网络全局信息估计,使所有节点快速获得网络全局信息。合理的数据包选择机制使得最终编码度分布趋于期望的度分布。分析和仿真结果表明,与具有代表性的分布式存储策略相比,该方法大幅度减少了数据包传输时的随机漫步步长,同时提高了译码性能,简单易行。展开更多
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders causing patients to seek medical treatment. It is relatively resource intensive and the source of significant morbidity. Recent insig...Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders causing patients to seek medical treatment. It is relatively resource intensive and the source of significant morbidity. Recent insights into the pathophysiology and treatment of IBS has given clinicians more options than ever to contend with this disorder. The purpose of our paper is to review older, “classic” treatments for IBS as well as newer agents and “alternative” therapies. We discuss the evidence base of these drugs and provide context to help develop appropriate treatment plans for IBS patients.展开更多
文摘针对空间信息网络(Space Information Network,SIN)节点存储资源严重受限及存储可靠性问题,该文提出一种基于LT(Luby Transform)码的分布式存储策略(Distributed Storage Strategy based on LT codes,DSSLT)。采用定向随机漫步机制,使得源数据包能够更快地遍历整个网络。在信息估计阶段利用基于ID的估计方法进行网络全局信息估计,使所有节点快速获得网络全局信息。合理的数据包选择机制使得最终编码度分布趋于期望的度分布。分析和仿真结果表明,与具有代表性的分布式存储策略相比,该方法大幅度减少了数据包传输时的随机漫步步长,同时提高了译码性能,简单易行。
文摘Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders causing patients to seek medical treatment. It is relatively resource intensive and the source of significant morbidity. Recent insights into the pathophysiology and treatment of IBS has given clinicians more options than ever to contend with this disorder. The purpose of our paper is to review older, “classic” treatments for IBS as well as newer agents and “alternative” therapies. We discuss the evidence base of these drugs and provide context to help develop appropriate treatment plans for IBS patients.
